Sucharu Prakash, Director of Quality Services at Texas Oncology, shared a post on LinkedIn:
“MRD impressive! Replace pCR in breast cancer – Who would have thought?
Ultrasensitive ctDNA detection better predictor of disease recurrence in patients receiving neoadjuvant therapy than pathologic complete response. This on the heels of other trials proving MRD based approach allows escalation/deescalation and shows survival benefit!
MRD continues to evolve and we are in the midst of a genomic revolution and huge global growth in the MRD space!
I get questions daily about minimal residual disease/ctDNA testing in solid tumors. Confusing arena- numerous labs offering the test, varying sensitivity, data not mature, tumor informed vs not…but data helps. On average, MRD positivity predicts relapse 6 to 12 months before imaging.
Exciting numerous trials in non small cell lung, breast, bladder, ovarian. Is one lab better than the other…not sure!
Coverage by payors much improved thanks to biomarker bill SB989. NCCN guidelines lagging behind. Look forward to more data and inclusion on pathways.”
Title: The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease
Authors: Natasha B. Hunter, Heather A. Parsons, Leslie Cope, Jenna V. Canzoniero, Fabio C. P. Navarro, Sherif El-Refai, Jesus D. Anampa, Joseph A. Sparano, Mothaffar Rimawi, Anna Maria Storniolo, Candace Mainor, Rita Nanda, Angela DeMichele, Gaorav P. Gupta, Erica J. Stringer-Reasor, Filipa Lynce, Erin F. Cobain, Shannon Puhalla, Rachel Jankowitz, Brent Rexer, Ingrid Mayer, E. Shelley Hwang, Kimberly Blackwell, Walid El Ayass, Young Lee, Carol Tweed, Mary Wilkinson, Angela Pennisi, Bonnie Sun, Pamela Wright, Julie R. Gralow, Richard Chen, Sean M. Boyle, Vered Stearns, Antonio C. Wolff, Ben Ho Park
Read The Full Article
Other articles about Breast Cancer on OncoDaily.